FDA Unveils Restitution Program for Three LaneLabs Products

WASHINGTON—The Food and Drug Administration (FDA) issued a consumer advisory about a restitution program featuring partial refunds of any monies paid for the purchase or shipping of any of three LaneLabs products. The program is in response to a 2004 ruling by the U.S. District Court for the District of New Jersey that LaneLabs USA LLC (www.lanelabs.com) and its president Andrew J. Lane marketed BeneFin, MGN-3 and SkinAnswer as treatments for HIV and cancer without FDA approval.

In accordance with the court, restitution is available to persons who purchased the LaneLabs products between Sept. 22, 1999, and July 12, 2004. The court appointed Newark, N.J.- based attorney Donald A. Robinson as Special Master to oversee the restitution process. Also, Gilardi & Co. LLC has been retained to assist with the restitution process.

FDA advised claims should be submitted to: LaneLabs Restitution Fund c/o Gilardi & Co. LLC, P.O. Box 808011, Petaluma, CA 94975-8011, and the completed claim form must be postmarked no later than Oct. 30, 2006. A copy of the claim form is available online (www.gilardi.com/lanelabs/), and questions can be directed to Gilardi via phone at (866) 431-8716.